I've yet to see a stock message board where someone didn't indicate a buyout was in the works. I've even seen many companies, like KERX honestly solicit a buyout, but it simply doesn't happen. IMHO about 99.9% of all the rumored buyouts never occur, and probably over 90% of those where buyouts are openly sought.
It's not that no one is interested in buying, it's because in the mind of the seller, the buyer wants to steal the company, while in the mind of the buyer, the seller is totally unrealistic about what the company's worth. Sadly big Pharma often buys poorly funded biotechs for a tiny fraction of what they should be worth, but when you're fighting to make payroll for another month, you may accept almost anything that's offered. Fortunately, neither AEZS or KERX is yet in that position.
When there's billions at stake in multiple cancers worldwide anything can and will happen. Fortunately for AEZS they have th patent in hand preventing anyone from building an analog of the drug Perifosine.
Inquiring minds want to hear from Keryx:
Perifosine/Capecitabine OS numbers
Capecitabine/Placebo OS numbers
Perifosine/Capecitabine secondary endpoint numbers
Perifosine/Capecitabine tertiary endpoint numbers
The Peri/Cap trial's 360 event date trigging unblinding
Plausible reason for Capecitabine's peak performance
Exactly why I think the plug was pulled on Peri the way it was: Very strange for such an anticipated PIII trial to end so devoid of communication. Perhaps Peri really works and this is someone's way of stomping the premium in pps to keep a buyout on the cheap and then come back with a re-energized Peri trial. Sick to think but people are greedy.